WO2012006181A3 - Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer - Google Patents

Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer Download PDF

Info

Publication number
WO2012006181A3
WO2012006181A3 PCT/US2011/042436 US2011042436W WO2012006181A3 WO 2012006181 A3 WO2012006181 A3 WO 2012006181A3 US 2011042436 W US2011042436 W US 2011042436W WO 2012006181 A3 WO2012006181 A3 WO 2012006181A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
cancer
treatment
inhibiting oncogenic
Prior art date
Application number
PCT/US2011/042436
Other languages
English (en)
Other versions
WO2012006181A2 (fr
Inventor
Josep M. Llovet
Sara Toffanin
Radoslav Savic
Original Assignee
Mount Sinai School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School Of Medicine filed Critical Mount Sinai School Of Medicine
Publication of WO2012006181A2 publication Critical patent/WO2012006181A2/fr
Publication of WO2012006181A3 publication Critical patent/WO2012006181A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des inhibiteurs de micro-ARN et des méthodes pour leur utilisation. Plus particulièrement, l'invention concerne des compositions et des méthodes de traitement de carcinomes hépatocellulaires à l'aide d'inhibiteurs de molécules de micro-ARN surexprimées dans le locus chromosomique 19q13.41 (C19MC).
PCT/US2011/042436 2010-06-29 2011-06-29 Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer WO2012006181A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35977010P 2010-06-29 2010-06-29
US61/359,770 2010-06-29

Publications (2)

Publication Number Publication Date
WO2012006181A2 WO2012006181A2 (fr) 2012-01-12
WO2012006181A3 true WO2012006181A3 (fr) 2012-04-26

Family

ID=45441752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/042436 WO2012006181A2 (fr) 2010-06-29 2011-06-29 Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2012006181A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130749A2 (fr) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification de mutations dans les glycoprotéines d'enveloppe de virus herpès simplex qui permettent ou augmentent le reciblage de vecteur vers de nouveaux récepteurs non-hsv
RS60318B1 (sr) * 2012-08-01 2020-07-31 Ikaika Therapeutics Llc Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitela
ES2810800T3 (es) 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Vector de HSV oncolítico
EA201791644A1 (ru) 2015-01-20 2018-01-31 Мираджен Терапьютикс, Инк. Ингибиторы mir-92 и их применение
RU2749050C2 (ru) 2016-01-27 2021-06-03 Онкорус, Инк. Онколитические вирусные векторы и их применение
WO2017210735A1 (fr) * 2016-06-07 2017-12-14 Garvan Institute Of Medical Research Méthodes de traitement du neuroblastome et réactifs à cet effet
US11427625B2 (en) 2016-06-14 2022-08-30 University of Pittsburgh—of the Commonwealth System of Higher Education Expression of NKG2D activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
BR112019000015A2 (pt) 2016-06-30 2019-04-24 Oncorus, Inc. distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
WO2018047148A1 (fr) * 2016-09-12 2018-03-15 Novartis Ag Composés pour inhibition du miarn
EP3589371A4 (fr) * 2017-03-02 2020-11-25 Youhealth Oncotech, Limited Marqueurs de méthylation pour diagnostiquer un carcinome hépatocellulaire et un cancer du poumon
EP3658165A4 (fr) 2017-07-26 2021-09-01 Oncorus, Inc. Vecteurs viraux oncolytiques et leurs utilisations
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
CN114480399A (zh) * 2022-03-17 2022-05-13 江苏医药职业学院 降低CPB1基因表达的siRNA、重组载体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
US20090220589A1 (en) * 2008-03-01 2009-09-03 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
US20090226375A1 (en) * 2008-02-21 2009-09-10 Eric Olson MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
US20090226375A1 (en) * 2008-02-21 2009-09-10 Eric Olson MICRO-RNAs THAT MODULATE SMOOTH MUSCLE PROLIFERATION AND DIFFERENTIATION AND USES THEREOF
US20090220589A1 (en) * 2008-03-01 2009-09-03 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RIPPE ET AL.: "The Two Stem Cell MicroRNA Gene Clusters C19MC and miR-371-3 Are Activated by Specific Chromosomal Rearrangements in a Subgroup of Thyroid Adenomas.", PLOS ONE, vol. 5, no. 3, 3 March 2010 (2010-03-03), pages 1 - 11, XP002607044, DOI: doi:10.1371/JOURNAL.PONE.0009485 *
TOFFANIN ET AL.: "MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a", GASTROENTEROLOGY, vol. 140, no. 5, May 2011 (2011-05-01), pages 1618 - 1628 *

Also Published As

Publication number Publication date
WO2012006181A2 (fr) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2012006181A3 (fr) Compositions et procédés pour l'inhibition de micro-arn oncogènes et le traitement du cancer
WO2012103059A3 (fr) Inhibiteurs de bcl-2/bcl-xl et méthodes thérapeutiques les utilisant
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
WO2008137867A3 (fr) Compositions comportant des agents thérapeutiques mir34 pour traiter le cancer
IL205307A0 (en) Targeting micrornas for the treatment of liver cancer
SI2358697T1 (sl) Spojine izoindolina za uporabo pri zdravljenju raka
WO2009137462A3 (fr) Procédés de traitement de troubles cognitifs à l'aide d'inhibiteurs de l'histone désacétylase
WO2010045345A3 (fr) Procédé de traitement
EP2429292A4 (fr) Composés et compositions comprenant des inhibiteurs des cdk et méthodes de traitement du cancer
WO2011037643A3 (fr) Compositions et procédés de détection et de traitement de carcinomes de la prostate
NZ626359A (en) Antisense molecules and methods for treating pathologies
HK1159498A1 (en) Methods and compositions for the treatment of cancer
WO2013023084A3 (fr) Procédés et compositions pour l'inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2012024396A3 (fr) Compositions et méthodes permettant d'administrer des molécules d'acide nucléique et de traiter un cancer
WO2012170776A3 (fr) Procédés de détermination du pronostic d'un patient pour la récurrence d'un cancer de la prostate et/ou déterminer une évolution de traitement pour un cancer de la prostate après une prostatectomie radicale
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
EP2224919A4 (fr) Méthodes et compositions de traitement du cancer, des tumeurs et des troubles associés aux tumeurs
EP2569014A4 (fr) Procédés de traitement
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
WO2008092099A8 (fr) Compositions et procédés de traitement de malignités hématopoïétiques
WO2015032800A3 (fr) Compositions et procédés d'induction de la sénescence dans des cellules cancéreuses
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2010072770A3 (fr) Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial
HK1212218A1 (en) Organoarsenic compounds and methods for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804199

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804199

Country of ref document: EP

Kind code of ref document: A2